Biological drugs in the treatment of atopic diseases in pediatric patients

Abstract

The complexity of the treatment of atopic diseases, including bronchial asthma, atopic dermatitis, and chronic urticaria, in pediatric patients lies in the detrimental effect of first-line drugs (glucocorticoids) on children's health and in the low prevalence of types of biological preparations due to limited data on their efficacy and safety, especially for the child population. The work presents a review of data on therapy with biological preparations in various pathological conditions, their effectiveness and safety in the long term. The aim of the review is to summarize the data on the treatment of atopic diseases with biological preparations. Materials and methods. We identified putatively relevant studies by searching MEDLINE, SCOPUS, PubMed, and Google Scholar electronic databases over the past 7 years using the terms: bronchial asthma; chronic urticaria; atopic dermatitis; biological preparations; omalizumab; dupilumab; mepolizumab; safety; monoclonal antibodies; efficiency. Further, according to the inclusion and exclusion criteria, as well as the independent selection of all authors, the suitable sources were selected and the review was compiled. Results. At the moment, there are not enough long-term studies on this topic, especially in pediatric practice. However, the existing ones allow drawing a preliminary conclusion about the prospects for further study of this topic in the treatment of atopic diseases.